December 20, 2024 Cleantech company Chromafora to tackle widespread chemical pollution with €22.5 million EU backing Read more
December 18, 2024 Mendus and UMCG announce positive topline data from the ALISON trial with vididencel in ovarian cancer Read more
December 18, 2024 Phenocell and Amarna Therapeutics Awarded Eurostars Grant to Assess a Gene Therapy for Dry AMD using a novel 3-dimensional iPSC-derived Retinal Model of the Disease Read more
December 12, 2024 Egetis receives positive CHMP opinion for Emcitate® (tiratricol) for the treatment of MCT8 deficiency Read more
December 9, 2024 Updated data from the ADVANCE II Phase 2 trial presented at ASH demonstrate durable survival of AML patients treated with vididencel Read more
December 4, 2024 Egetis has decided to explore RTH-beta as the next indication for tiratricol (Emcitate®) Read more
December 3, 2024 Amarna Therapeutics partners with NorthX Biologics to advance Nimvec™ AM510 gene therapy development Read more
November 20, 2024 Vitara Biomedical Raises $50 Million in Additional Financing and Names Kim Rodriguez as New Chief Executive Officer Read more
November 13, 2024 Microbiotica Announces First Patient Dosed in its Phase 1b Trial (COMPOSER-1) of MB310, a Precision Microbiome Medicine, in Ulcerative Colitis Patients Read more
November 1, 2024 Xintela’s main owner Flerie undertakes to exercise warrants TO3 of approximately SEK 28 million and provides a bridge loan of SEK 9 million Read more
October 23, 2024 Toleranzia receives approximately SEK 37 million through the warrants of series TO4 which were exercised to approximately 85 percent Read more
October 7, 2024 Microbiotica Announces First Patient Dosed in its International Phase 1b Trial, MELODY-1 of MB097 Precision Microbiome Co-Therapy in Advanced Melanoma Read more
October 2, 2024 Toleranzia submits a clinical trial application (CTA) for the drug candidate TOL2 for the treatment of myasthenia gravis Read more
October 2, 2024 NorthX Biologics strengthens leadership team with Magnus Gustafsson as Chief Commercial Officer Read more
October 1, 2024 Egetis Therapeutics has successfully carried out directed share issuances amounting to SEK 300 million Read more
September 26, 2024 Nanologica Receives Order for NLAB Saga® Worth approx. SEK 3,7 Million from Returning Customer in China Read more
September 20, 2024 Xspray Pharma Announces Positive FDA Meeting and Plans for Dasynoc NDA Resubmission Read more
September 19, 2024 Egetis submits a patent application to the United States Patent and Trademark Office for “Processes of Preparation” of tiratricol Read more
September 17, 2024 AnaCardio successfully completes first part of AC01 HFrEF study and provides a clinical update Read more
